MondayNightIBD
Decoding TL1A Blockade: Emerging Therapeutic Strategies for Bridging Critical Gaps in IBD Management

This program is jointly provided by Partners for Global Education Group (Global) and Bonum CE, in partnership with MondayNightIBD.
Supported by an educational grant from Sanofi.

Program Overview

TL1A blockade represents an attractive strategy for treating IBD associated mucosal inflammation. Pathway inhibition reduces inflammatory responses while preserving baseline immunity, demonstrating efficacy in colitis and asthma animal models. Several TL1A-targeted agents show exceptional promise addressing both intestinal inflammation and fibrosis.

Emerging TL1A inhibitors potentially offer clinical benefits. Higher remission rates, sustained efficacy, and favorable safety profiles position them as promising options in IBD's evolving treatment landscape. This CME-certified, MondayNightIBD program helps health care professionals treating pts w/ IBD to be knowledgeable about this novel MOA and data supporting their use as TL1A therapies move into clinical practice in the near future.

Please be sure to join for any or all the events listed below. Activity links will be “live” on each activity page on the program launch date. Video and tweetorial activities can be viewed live and will also be archived for later viewing on the individual activity pages linked below. Clinical Case Conversations and #PatientExperience discussions can be viewed on X/Twitter by navigating to www.x.com/mondaynightibd.

Program
Faculty

Aline Charabaty, MD, FACG, AGAF (moderator)
Professor of Medicine
Director of the Inflammatory Bowel Disease Program
Division of Gastroenterology and Hepatology
University of Maryland Medical Center
Baltimore, MD

Vipul Jairath, MBChB, DPhil (guest faculty)
Professor of Medicine
Departments of Medicine, Epidemiology and Biostatistics
John and Susan McDonald Endowed Chair in IBD Clinical Research Director
Advanced IBD Fellowship Program
Associate Chair (Research)
Department of Medicine
Schulich School of Medicine & Dentistry
Western University
London, Ontario

Tina Aswani Omprakash, MPH (guest faculty)
Patient Advocate
Chief Executive Officer
SAIA (Strategic Alliance for Intercultural Advocacy in GI)
New York, NY

Learning Objectives

After completing this activity series, learners should be better able to:
1. Identify the current unmet clinical needs in IBD management, including remission rates, fibrotic complications, and patient treatment priorities.
2. Explain the pathophysiological mechanisms of the TL1A/DR3 pathway in IBD-associated inflammation and fibrosis.
3. Compare emerging TL1A-targeted therapies based on clinical trial fficacy, safety profiles, and potential patient populations.

Upcoming Activities Activities

  • MondayNightIBD Novel MOAs Clinical Conversation

    This MNIBD Clinical Convo activity focuses on the translation of data supporting the use of TL1As as a therapeutic option in IBD.

    View Activity